-+ 0.00%
-+ 0.00%
-+ 0.00%

Sihuan Pharma Subsidiary Xuanzhu's Bireociclib Gains China Reimbursement for First-Line Breast Cancer Treatment

PUBT·11/16/2026 08:40:35
Listen to the news
Sihuan Pharma Subsidiary Xuanzhu's Bireociclib Gains China Reimbursement for First-Line Breast Cancer Treatment
  • Sihuan Pharmaceutical's non-wholly-owned subsidiary Xuanzhu Biopharm secured inclusion of Bireociclib's new indication in China's 2026 national reimbursement drug list.
  • Coverage includes Bireociclib combined with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer.
  • All three China-approved Bireociclib indications are now listed. The new list takes effect Jan. 1, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12413878), on November 16, 2026, and is solely responsible for the information contained therein.